HO 0309

Drug Profile

HO 0309

Alternative Names: HO/03/09

Latest Information Update: 19 Feb 2016

Price : $50

At a glance

  • Originator HealOr
  • Class Antiulcers; Chemoprotectants
  • Mechanism of Action Epithelial cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Mucositis

Most Recent Events

  • 19 Feb 2016 No recent reports on development identified - Phase-I/II for Mucositis in Israel (Topical)
  • 14 Jul 2011 Phase-I/II clinical trials in Mucositis (CAMS, chemotherapy associated mouth sores) in Israel (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top